Market Overview:
The global glatiramer drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of multiple sclerosis (MS) and rising demand for better treatment options. Based on type, the global glatiramer drugs market is segmented into brand medicine and generic drug. The brand medicine segment is expected to account for a larger share of the market in 2018 owing to its higher price point and better efficacy as compared to generic drugs. However, the generic drug segment is projected to grow at a higher CAGR during the forecast period due its lower cost and growing preference for generics over branded medicines. Based on application, the global glatiramer drugs market is divided into hospital pharmacies, retail pharmacies, and other applications such as clinics or doctor’s offices. The hospital pharmacies segment accounted for majority of revenue share in 2017 owing high utilization rates across hospitals globally coupled with rising number of MS patients being admitted in hospitals for treatment purposes.
Product Definition:
Glatiramer acetate (brand name Copaxone) is a drug used to treat multiple sclerosis. It is a synthetic protein composed of four amino acids, which are naturally found in human cells. Glatiramer acetate was approved by the U.S.
Brand Medicine:
The term brand medicine is generally used for drugs that have a well-established reputation, both clinically and commercially. Brand names are often used by pharmaceutical companies to market their products in the absence of any specific product differentiation. However, there exist some notable differences between generic and branded medicines; generic medicines are usually cheaper than branded counterparts. This may be attributed to the fact that patent protection for certain drugs has expired as stated by regulatory agencies such as FDA (Food & Drug Administration) in U.
Generic Drug:
A generic drug is a pharmaceutical product that has an active ingredient similar to that of a branded drug but is not the exact same as the patented medicine. The generic version of the medication may be approved by the FDA and sold in place of or along with the brand-name version. Sales of these drugs are estimated to increase substantially over coming years owing to increasing demand for cost-effective medicines, rising competition between healthcare providers, and growing consumer awareness regarding health insurance plans offered by governments around world.
Application Insights:
Glatiramer drugs are used for the treatment of multiple sclerosis in patients who have not been able to respond to other therapies. The growing prevalence of the disease and increasing number of drug-resistant cases are expected to drive this segment over the forecast period.
The hospital segment dominated the global glatiramer drugs market, accounting for a revenue share of more than 60% in 2017 owing to an increase in patient admissions due largely to a rise in cardiovascular diseases and cancer cases across various regions including North America and Europe. This is anticipated further fuel demand for these medicines at hospitals globally.
Pharmacy application is projected register notable growth with a CAGR around 10% from 2018 to 2030, on account of rising awareness about availability of generic medicines coupled with growing use as second line therapy owing largely due lack efficacy against disease progression or non-response by first line therapy such as beta interferon or natalizumab among others.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of patients suffering from multiple sclerosis and high healthcare expenditure. In addition, increasing government funding for research & development activities is also expected to drive this regional market over the forecast period. For instance, in March 2018, an investment worth USD X million was made by FUJIFILM Diosynth Biotechnologies US Inc for R&D on gluten-free products. The company plans to use these funds for drug discovery programs targeting autoimmune diseases such as ulcerative colitis and Crohn’s disease.
Asia Pacific is expected to grow at a lucrative rate during the forecast period due to rising disposable income coupled with growing awareness about brand medicines among patients suffering from multiple sclerosis (MS). Moreover, increasing cases of infectious diseases are also driving demand for glatiramer drugs in countries such as India and China which will propel growth during the forecast period.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global Glatiramer Drugs market is expected to grow at a CAGR of XX% during the forecast period owing to the increasing incidence of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and Crohn’s disease.
- Rising awareness about Glatiramer Drugs: There is a growing awareness among people about the benefits of using Glatiramer Drugs for treating various autoimmune diseases. This is likely to boost the demand for Glatiramer Drugs in the coming years.
- Technological advancements in drug delivery systems: The development of novel drug delivery systems has revolutionized the treatment landscape for various chronic diseases including autoimmune disorders. This is likely to create new opportunities for players operating in the global Glatiramer Drugs market over the forecast period.
- Growing investments by key players: Key players are investing heavily in research and development activities with an aim to develop novel therapies for treating various types of autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and Crohn’s disease etcetera .This is anticipated to fuel growth prospects for this market during 2018-2025 timeframe . 5) Emerging markets offer significant growth potential: A large number of patients suffering from different types auto immune disorders are yet untapped in emerging markets across Latin America Asia Pacific ,and Africa regions offers significant growth potentialforplayersoperatinginglobalGlatriameralDrugsmark
Scope Of The Report
Report Attributes
Report Details
Report Title
Glatiramer Drugs Market Research Report
By Type
Brand Medicine, Generic Drug
By Application
Hospital, Pharmacy, Other
By Companies
Teva, NATCO Pharma, Mylan, Novartis, HYBIO
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Glatiramer Drugs Market Report Segments:
The global Glatiramer Drugs market is segmented on the basis of:
Types
Brand Medicine, Generic Drug
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- NATCO Pharma
- Mylan
- Novartis
- HYBIO
Highlights of The Glatiramer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Brand Medicine
- Generic Drug
- By Application:
- Hospital
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glatiramer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glatiramer drugs are a class of medications used to treat multiple sclerosis (MS). Glatiramer is an antibody that blocks the action of a protein called myelin sheath glycoprotein (MSG). This reduces the inflammation and damage caused by MS.
Some of the key players operating in the glatiramer drugs market are Teva, NATCO Pharma, Mylan, Novartis, HYBIO.
The glatiramer drugs market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Glatiramer Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Glatiramer Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Glatiramer Drugs Market - Supply Chain
4.5. Global Glatiramer Drugs Market Forecast
4.5.1. Glatiramer Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Glatiramer Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Glatiramer Drugs Market Absolute $ Opportunity
5. Global Glatiramer Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Glatiramer Drugs Market Size and Volume Forecast by Type
5.3.1. Brand Medicine
5.3.2. Generic Drug
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Glatiramer Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Glatiramer Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Pharmacy
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Glatiramer Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Glatiramer Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Glatiramer Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Glatiramer Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Glatiramer Drugs Demand Share Forecast, 2019-2026
9. North America Glatiramer Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Glatiramer Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Glatiramer Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Pharmacy
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Glatiramer Drugs Market Size and Volume Forecast by Type
9.7.1. Brand Medicine
9.7.2. Generic Drug
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Glatiramer Drugs Demand Share Forecast, 2019-2026
10. Latin America Glatiramer Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Glatiramer Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Glatiramer Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Pharmacy
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Glatiramer Drugs Market Size and Volume Forecast by Type
10.7.1. Brand Medicine
10.7.2. Generic Drug
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Glatiramer Drugs Demand Share Forecast, 2019-2026
11. Europe Glatiramer Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Glatiramer Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Glatiramer Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Pharmacy
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Glatiramer Drugs Market Size and Volume Forecast by Type
11.7.1. Brand Medicine
11.7.2. Generic Drug
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Glatiramer Drugs Demand Share, 2019-2026
12. Asia Pacific Glatiramer Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Glatiramer Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Glatiramer Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Pharmacy
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Glatiramer Drugs Market Size and Volume Forecast by Type
12.7.1. Brand Medicine
12.7.2. Generic Drug
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Glatiramer Drugs Demand Share, 2019-2026
13. Middle East & Africa Glatiramer Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Glatiramer Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Glatiramer Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Pharmacy
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Glatiramer Drugs Market Size and Volume Forecast by Type
13.7.1. Brand Medicine
13.7.2. Generic Drug
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Glatiramer Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Glatiramer Drugs Market: Market Share Analysis
14.2. Glatiramer Drugs Distributors and Customers
14.3. Glatiramer Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Teva
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. NATCO Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Mylan
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. HYBIO
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
